

Title: The role of sodium channels in sudden unexpected death in pediatrics

Anne M. Roctus^{1,2}, Richard D. Goldstein^{2,3}, Ingrid A. Holm^{2,3,4}, Catherine A. Brownstein^{2,3,4}, Eduardo Pérez-Palma⁵, Dennis Lal^{6,7}, Annapurna H. Poduri^{1,2,6*}

Short running title: Sodium channels in sudden unexpected death in pediatrics

¹ Department of Neurology, Boston Children's Hospital, Boston, MA, USA

² Robert's Program on Sudden Death in Pediatrics, Boston Children's Hospital, Boston, MA, USA

³ Department of Pediatrics, Harvard Medical School, Boston, MA, USA

⁴ Department of Medicine, Division of Genetics and Genomics and the Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, MA, USA

⁵ Cologne Center for Genomics, University of Cologne, Cologne, Germany

⁶ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA

⁷ Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA

* Corresponding author

E-mail: Annapurna.Poduri@childrens.harvard.edu (A.H.P.)

Abstract

Sudden Unexpected Death in Pediatrics (SUDP) is a tragic condition with hypothesized multifactorial etiology. While there is recent evidence implicating genes related to cardiac arrhythmia and epilepsy as genetic risk factors contributing to some cases of SUDP, the underlying mechanisms of SUDP remain under active investigation. SUDP encompasses Sudden Infant Death Syndrome (SIDS) and Sudden Unexplained Death in Childhood (SUDC), affecting children under and over 1 year of age, respectively. The presence of developmental hippocampal malformations in many children with SIDS and SUDC suggests that a subset of patients may share epilepsy-related mechanisms with Sudden Unexplained Death in Epilepsy Patients (SUDEP). Pathogenic variants in both epilepsy- and arrhythmia-related sodium channel genes have recently been identified in patients with SIDS, SUDC, and SUDEP.

We performed a candidate gene analysis for genes encoding sodium channel subunits in whole exome sequencing (WES) data from 73 SUDP patients. After a thorough literature review, we mapped all reported SUDP-associated sodium channel variants alongside variants from the population on a structural protein model to evaluate whether patient variants clustered in important protein domains compared to controls.

In our cohort, 13 variants met criteria for pathogenicity or potential pathogenicity. While *SCN1A*, *SCN1B*, and *SCN5A* have established disease associations, we also considered variants in the paralogs *SCN3A*, *SCN4A* and *SCN9A*. Overall, the patient-associated variants clustered at conserved amino acid sites across the sodium channel gene family that do not tolerate variation in these genes.

This study provides a molecular overview of sodium channel variants present in cases with SUDP and reveals key amino acid sites that do not tolerate variation across the SCN paralog family. Further research will lead to an improved understanding of the contribution of sodium channels to SUDP, with a goal of one day implementing prevention strategies to avoid untimely deaths in at-risk children.

Author Summary

The sudden unexplained death of an infant or a child is a tragic event, which is likely caused by the complex interaction of multiple factors. Besides environmental factors, genes related to epilepsy and cardiac arrhythmia have been identified as risk factors. The sodium channel family encompasses genes, related to both cardiac arrhythmia as well as epilepsy, whose proteins share structural homology. We evaluated sodium channel gene variants in our cohort, examined all known variants in sodium genes in SUDP patients from the literature, and mapped patient variants alongside variants from the population on a 3D protein model. The patient variants clustered at conserved amino acid sites with low rates of variation in the general population, not only in the particular gene involved but also in the gene family. This study illustrates that sodium channel variants contribute to the complex phenotype of sudden death in pediatrics, suggesting complex mechanisms of neurologic and/or cardiac dysfunction contributing to death.

Introduction

Sudden Unexpected Death in Pediatrics (SUDP) encompasses a tragic set of conditions, including Sudden Infant Death Syndrome (SIDS) and Sudden Unexplained Death in Childhood (SUDC), affecting children under and over 1 year of age, respectively. These conditions are hypothesized to involve heterogeneous and multifactorial etiologies, conceptualized as a 'triple-risk' model with a convergence of

intrinsic, developmental, and environmental vulnerabilities contributing to death [1,2]. We have reported developmental hippocampal malformations in greater than 40% of children with SIDS and SUDC [3,4], suggesting that a subset of SIDS and SUDC is linked to epilepsy-related mechanisms since such hippocampal lesions have been classically associated with temporal lobe epilepsy [5]. The association between epilepsy and sudden death, demonstrated most clearly in sudden unexpected death in epilepsy (SUDEP), may well extend to SIDS and SUDC in patients with these lesions, which have been called ‘epilepsy *in situ*’ [6]. While the terminal mechanisms of SUDP and SUDEP remain speculative [7,8], there is active investigation into the role of genetic factors involving genes related to epilepsy [9,10] as well as cardiac arrhythmias [11,12].

Voltage-gated sodium channels (VGSCs) are a highly conserved family of proteins—expressed in excitable tissue in heart, central nervous system, peripheral nervous system, and muscle—that are essential for the generation and propagation of action potentials. Interestingly, pathogenic variants in both arrhythmia- and epilepsy-related VGSCs have been identified in patients with SIDS, SUDC, and SUDEP [9,12–30]. In humans, nine different pore-forming α -subunits have been identified ($\text{Na}_v1.1$ -1.9 encoding for *SCN1A-SCN5A* and *SCN8A-SCN11A*) [31,32]. $\text{Na}_v1.1$, 1.2, 1.3 and 1.6 are the primary sodium channel subunits expressed in the central nervous system, $\text{Na}_v1.7$, 1.8 and 1.9 in the peripheral nervous system, $\text{Na}_v1.4$ in skeletal muscle, and $\text{Na}_v1.5$ in the heart. The pore-forming α -subunit is composed of four homologous domains, each containing six transmembrane α -helical segments (S1-S6). In addition, there are five different β -subunits ($\beta1$, $\beta1B$, $\beta2$, $\beta3$, $\beta4$) encoded by *SCN1B-SCN4B* [33]. The tissue-specific expression profiles of α -subunits and β -subunits are shown in Table 1. Variants in the cardiac-expressed *SCN5A* [12–26] gene are reported most frequently in association with SIDS and SUDC, but variants in *SCN1A* [9,27], *SCN4A* [34], *SCN10A* [35], *SCN1B* [12,35–38], *SCN3B* [15,39] and *SCN4B* [39] have also

been reported. In addition, variants in *SCN1A* [40,41], *SCN2A* [28,42] and *SCN8A* [29,30,42] have been associated with SUDEP.

Table 1. Voltage-gated sodium channels expression and disease associations

Gene	Protein	Distribution	Associated human disease
SCN1A	Nav1.1	CNS, heart	DS, GEFS+, FS+, familial autism, FHM3, SUDEP
SCN2A	Nav1.2	CNS	DS, GEFS+, OS, EOEE, BFNIS
SCN3A	Nav1.3	CNS, heart	Unclear, contributing to neuronal hyperexcitability/ epilepsy?
SCN4A	Nav1.4	Skeletal muscle	PAM, PMC, HyperPP, HypoPP, SNEL
SCN5A	Nav1.5	Skeletal muscle, heart, CNS	AF, AS, BS, DCM, LQTS, PCCD, SIDS, SSS, SUDEP
SCN8A	Nav1.6	CNS, PNS	EOEE, cognitive impairment, paralysis, ataxia, dystonia
SCN9A	Nav1.7	PNS	CIP, IEM, PEPD, PPN
SCN10A	Nav1.8	PNS	PPN
SCN11A	Nav1.9	PNS	PPN
SCN1B	$\beta 1$	CNS, PNS, heart	AF, BS, DS, GEFS+, LQTS, PCCD, TLE
SCN2B	$\beta 2$	CNS, PNS, heart	AF, BS
SCN3B	$\beta 3$	CNS, PNS, heart	AF, BS, PCCD, SIDS, ventricular fibrillation
SCN4B	$\beta 4$	CNS, PNS, heart	LQTS, SIDS
SCN1B	$\beta 1B$	Fetal CNS, PNS, heart	BS, PCCD, epilepsy

Legend: Modified with permission from Brunklaus et al [43].

AF, Atrial fibrillation; AS, atrial standstill; BFNIS, benign familial neonatal-infantile seizures; BS, Brugada syndrome; CIP, channelopathy-associated insensitivity to pain; CNS, central nervous system; DCM, dilated cardiomyopathy; DS, Dravet syndrome; EOEE, early-onset epileptic encephalopathy; FHM3, familial hemiplegic migraine type 3; FS+, febrile seizures plus; GEFS+, genetic epilepsy with febrile seizures plus; HyperPP, hyperkalemic periodic paralysis, HypoPP, hypokalemic periodic paralysis; IEM, inherited erythromelalgia; LQTS, long QT syndrome; OS, Ohtahara syndrome; PAM, potassium-aggravated myotonia; PCCD, progressive cardiac conduction disease; PEPD, paroxysmal extreme pain disorder formally known as familial rectal pain syndrome; PMC, paramyotonia congenital; PNS, peripheral nervous system; PPN, painful peripheral neuropathies; SIDS, sudden infant death syndrome; SNEL, severe neonatal episodic laryngospasm; SSS, sick sinus syndrome; SUDEP, sudden unexplained death in epilepsy; TLE, temporal lobe epilepsy.

Given the common evolutionary origin and expression pattern of sodium channel subunits expressed across cardiac and neurologic tissues, we performed a candidate gene analysis for variants in genes encoding these proteins and their paralogs using whole exome sequencing (WES) data from 73 patients with SUDP. In addition, we performed a structure-based assessment of all novel and reported variants in human sodium channels in patients with SUDP vs. controls.

Results

Genetics and clinical characteristics of our cases

We identified 13 variants that we determined to be pathogenic or likely pathogenic in genes encoding for VGSCs in 11 patients, using ACMG criteria [44] (Table 2). The age of death across the 11 patients with variants in VGSC-encoding genes ranged from 7 weeks to 8 years, with 9/11 (81%) patients younger than 6 months at the time of death. Eight patients had hippocampal malformations as assessed by detailed neuropathological examination, and 1 patient had a normal hippocampus. For 2 other patients, detailed neuropathological analysis was not possible. Full clinical and molecular data for all 11 patients are listed in Table 2. Notably, one patient had two variants in *SCN1A* (p.Leu1296Met, p.Glu1308Asp) (reported previously)[9], one patient had a variant in *SCN3A* (p.Ala1804Val) and in *SCN10A* (c.4386+1G>C), and two siblings carried the same variant in *SCN1B* (p.Trp179Ter).

Table 2. Variants in voltage-gated sodium channel genes in our cohort.

Gene	Pat-ient	cDNA, protein	AF	Pathogenicity predictions	Inherit-ance	Age	HC	Additional notes
<i>SCN1A</i>	1	3886T>A, L1296M	8.17E-06	PP-2, 0.979; SIFT, 0.001	N/A	7 we	Abnormal DG	
	1	3924A>T, E1308D	0.0006416	PP-2, 0.727; SIFT, 0.281	N/A	7 we		
	2	2045G>T, G682V	4.07E-06	PP-2, 0.478; SIFT, 0.003	N/A	2 mo	Abnormal DG	
	3	182T>C, L61P	0	PP-2, 0.783; SIFT, 0	N/A	20 mo	Abnormal DG	History of atypical FS
<i>SCN3A</i>	4	5411C>T, A1804V	2.44E-05	PP-2, 0.998; SIFT, 0	N/A	4 mo	N/A	
<i>SCN4A</i>	5	2171A>G, K724R	0	PP-2, 0.953; SIFT, 0.001	inh	5 mo	Normal	Megalencephaly, bilateral open opercula, bilateral small STG, chronic hemorrhages, acute HIE
	6	307T>G, F103V	2.03E-05	PP-2, 0.73; SIFT, 0.001	inh	3 mo	Abnormal DG	Megalencephaly, mild gliosis of CWM, CerWM, inferior olive, tegmentum
<i>SCN5A</i>	7	283G>A, V95I	3.25E-05	PP-2, 0.979; SIFT, 0.001	inh	1.5 mo	Abnormal DG	
<i>SCN9A</i>	8	5624G>A, R1875Q	1.62E-05	PP-2, 0.734; SIFT, 0	inh	8 yrs	Abnormal DG	Cytomegaly in RF
<i>SCN10A</i>	4	4386+1G>C	1.22E-05	splicing (100%)	N/A	4 mo	N/A	
	9	305C>G, S102C	4.07E-06	PP-2, 0.701; SIFT, 0.002	inh	3 mo 22 d	Abnormal DG	Megalencephaly
<i>SCN1B</i>	10	536G>A, W179*	8.19E-06	nonsense	N/A	4 mo	Abnormal DG	Megalencephaly
	11	536G>A, W179*	8.19E-06	nonsense	N/A	2 mo	N/A	Megalencephaly

Legend: AF = allele frequency according to gnomAD; CWM = cerebral white matter; CerWM = cerebellar white matter; DG=dentate gyrus; FS = febrile seizures; HC = hippocampus; inh = inherited; mo = months; HIE = hypoxic ischemic encephalopathy; N/A=not available; PP-2 = Polyphen2; RF = reticular formation; SIFT = Sorting Intolerant From Tolerant; STG = superior temporal gyrus; we = weeks; yrs = years. For splicing variants, we used the splicing prediction score from Alamut Visual-2.10, which incorporates the splicing tools MaxEnt, NNSPLICE, and HSF. Variants highlighted in **bold** affect the same paralog position. Patient 1 and 2 have been reported previously.

Transcripts used: *SCN1A* (NM_001165963.1), *SCN3A* (NM_0006922.3), *SCN4A* (NM_000334.3), *SCN5A* (NM_198056.2), *SCN9A* (NM_002977.3), *SCN10A* (NM_006514.2), *SCN1B* (NM_199037.4), *SCN3B* (NM_018400.3), *SCN4B* (NM_174934.3).

Cases from the literature

We reviewed all variants in VGSC genes that have been reported in the literature in patients with SIDS and SUDC. We identified 74 variants in 99 patients affecting 72 different amino acid positions in the following genes: *SCN1A* (n=3), *SCN4A* (n=5), *SCN5A* (n=55), *SCN10A* (n=4), *SCN1B* (n=3), *SCN3B* (n=3), *SCN4B* (n=1).

Re-evaluation of all variants

Collectively, 13 patients' variants from our own cohort plus 99 patients' variants retrieved from literature comprise 84 variants affecting 82 different amino acid positions in 9 genes: *SCN1A* (n=4), *SCN3A* (n=1), *SCN4A* (n=8), *SCN5A* (n=56), *SCN9A* (n=1), *SCN10A* (n=6), *SCN1B* (n=4), *SCN3B* (n=3), *SCN4B* (n=1). Three of the variants included here were previously reported [9,27].

Evaluating variants in the literature with respect to allele frequency reported in the general population, 11/74 variants (15%) of the variants reported in the literature had an allele frequency higher than 0.001, arguing against their pathogenicity. In addition, using pathogenicity prediction scores, we identified 23 additional variants that were predicted to have a benign or neutral functional effect. In total, we considered that there was conflicting evidence of pathogenicity for 33 out of the 74 (45%) variants reported in literature, and 1 out of 74 (1%) was determined to be benign based on the high frequency in controls, lack of predicted functional effect *in silico*, and/or *in vivo* absence of functional effects resulting from the variants (S1 Table).

To further assess for evidence of variant pathogenicity, we determined the Parazscore for all missense variants. As expected, Parazscores from patient variants were significantly higher than those observed in gnomAD controls (p-value < 0.0001). The patients' variants that we determined to be pathogenic with the prediction tools were more likely to be located at strongly conserved family members (p=0.03) (i.e., greater

Parazscores) (Fig 1A). On the other hand, patients' variants that we determined to be conflicting or benign with the prediction scores were more likely present in less conserved regions ($p=0.0001$) (Fig 1B). Interestingly, 25 variants involved the 'alignment index position' of a VGSC variant reported in disease (S2 Table), which is unlikely to occur in the general population ($p\text{-value} < 0.0001$). Overall, we observed significant clustering of variants at conserved amino acid sites, notably with the same amino acid affected between *SCN1A/SCN5A* and *SCN5A/SCN9A* (S2 Table). The variants of two patients (Patients 6 and 9) in our cohort affected the same paralog position: *SCN4A* (p.Phe103Val) and *SCN10A* (p.Ser102Cys) ($p\text{-value} < 0.0001$). Both patients died at 3 months of age and had pathology notable for hippocampal granule cell dispersion with dentate gyrus bilamination (Table 2); both variants were inherited from a parent who had no history of epilepsy, febrile seizures, or other major illness. Three other patients of our cohort (Patients 1, 7 and 8) affected the same paralog position at respectively *SCN1A/SCN5A*, *SCN5A/SCN9A*, and *SCN5A/SCN10A*. Interestingly, all three patients had dentate gyrus bilamination (Table 2 and Supplementary Table 2).

Variant position and pathogenicity

Variants predicted to be pathogenic were more likely to be localized in the transmembrane regions of the protein ($p\text{-value} = 0.03$), which have been associated with severe channel dysfunction [45]. On the other hand, variants predicted to be conflicting or benign variants were more likely to be localized in the cytoplasm ($p\text{-value} = 0.0063$) (S1 Table, S1 Fig). Mapping of all Na_v channel variants on a 3-dimensional structural model was not informative (S2 Fig).

Discussion

We report 11 patients with 13 pathogenic or likely pathogenic variants in genes encoding for sodium channel subunits expressed in the brain and/or in the heart. Among the cases with variants presented here, 8 cases had hippocampal abnormalities but no history of seizures. None had a history of cardiac arrhythmia or other cardiac presentation prior to death. While *SCN1A* [9,27], *SCN1B* [12,35–37], and *SCN5A* [12–26] have strong prior associations with epilepsy, arrhythmia, and sudden death, we additionally considered variants in the following *SCN* paralogs: *SCN3A*, *SCN4A*, *SCN9A*, *SCN10A*. Surprisingly, only 1/13 (8%) of our own cohort of patients carried a variant in *SCN5A*, compared to 76/99 (77%) of the SIDS patients reported in literature. On the other hand, 4/13 (31%) of our own cohort compared to 4/99 (4%) patients of the literature carried a variant in *SCN1A*, three of which were recently reported [9,27].

Our literature review found 74 variants in 99 patients with SIDS, SIDS-like presentations, or SUDC affecting 72 different amino acid positions in a VGSC-related gene. 55/75 variants were present in *SCN5A*, reflecting in some cases the fact that this gene was specifically targeted in some series [13–16,20,21,24,46]. Since many of the VGSC variants reported in SIDS or SUDC were described before the current era of abundant publicly available control data, we re-evaluated all the variants reported in literature with this in mind. In a surprisingly high number of reported variants (45%), conflicting evidence argued against pathogenicity using current ACMG criteria. Analysis of the relatively modest number of variants in our cohort, coupled with a larger number from the literature, suggested that those variants we determined to be pathogenic or likely pathogenic by other metrics were most likely to be located in critical domains of the sodium channel protein—e.g., transmembrane domains. Alternatively, variants in control populations were randomly distributed throughout the genes. Variants considered pathogenic are enriched in conserved regions across gene family members. We hypothesized that variants in VGSC genes at certain conserved

positions might be associated with a risk for sudden death, independent of the tissue where the relevant gene is most highly expressed. This is illustrated by two patients in our cohort that carry a variant in respectively *SCN4A* and *SCN10A* at the same paralog position and 24 other variants from the literature that affect a paralog variant that is known to be disease-associated. When considering variant pathogenicity in a newly implicated VGSC-encoding gene, the position in the protein, with respect to paralogous proteins already implicated in sudden death, can provide additional evidence suggesting pathogenicity.

Ultimately, while all of these factors are taken into consideration when assessing pathogenicity, robustly conducted experimental evidence with adequate positive and negative control data should be sought when there is question regarding pathogenicity. Larger cohort studies will be required to more securely implicate a broader range of VGSC-related genes in SUDP. In addition, future studies that can incorporate trio sequencing, in which parental DNA can be made available to determine whether variants are *de novo* and thus more likely to be pathogenic with respect to a severe phenotype like sudden death, will contribute to our understanding of the role of this family of genes to sudden death. Initial studies in induced pluripotent stem cell (iPSC)-derived neurons and mouse models of *SCN1A*, traditionally associated with epilepsy, suggested cardiac and/or respiratory mechanisms of death [47,48]. Additional *in vitro* and *in vivo* studies of the sodium channel gene family will move us toward understanding the mechanisms through which variants in sodium channel-encoding genes contribute to sudden death.

Conclusions

Our analysis of a SUDP cohort and the present literature on sodium channel variants in SUDP cases, using population- and protein structure-based predictive models,

revealed 48 SCN variants. Importantly, in our cohort, the variants were found in children without prior histories of seizures yet with hippocampal abnormalities and without history or family history of cardiac arrhythmia. Overall, similar to those reported in prior studies, variants predicted to be pathogenic were more likely localized in the transmembrane regions of the protein. These findings provide evidence that sodium channel abnormalities contribute to the complex phenotype in SUDP involving central nervous system and/or cardiac rhythm dysfunction. Further, they suggest that future functional studies into the function of the sodium channels may elucidate the mechanisms through which variants in these genes underlie some cases of sudden death.

Methods

Ethics statement

The study has been approved by the Institutional Review Board of Boston Children's Hospital (approval number P00011014). Informed consent has been obtained from all participants.

Our cohort

DNA from 73 SUDP cases was obtained through the Massachusetts Office of the Chief Medical Examiner (OCME), Boston, MA and the Office of the Medical Examiner, San Diego, CA using consent procedures in accordance with Massachusetts and California Law. These cases included 42 singletons for whom parental samples were not available and for whom families could not be contacted, 28 trios consisting of probands and both parents, and 3 probands with one parent sample available. DNA extracted from whole blood or saliva underwent capture for exome sequencing using either the Agilent SureSelect XTHuman All Exon v4 or Illumina Rapid Capture Exome enrichment kit (Broad Institute, Cambridge, MA). Sequencing of 100bp paired end

reads was obtained using Illumina HiSeq (Illumina, San Diego, CA). Coverage was >90% or >80% meeting 20x coverage with the two methods respectively. Our data analysis and variant calling methods have been described previously [49]. We utilized the BCH (Boston Children`s Hospital) Connect Genomics Gateway integrated with the *WuXi NextCODE* analysis platform [50] for variant interrogation and analysis.

For each case, we performed a targeted initial analysis to identify variants in genes encoding for the human VGSC subunits. Candidate pathogenic variants were evaluated according to American College of Medical Genetics and Genomics (ACMG) criteria [44], including pathogenicity predictions from both Polyphen2 and SIFT and low population allele frequency (<0.001) according to the Genome Aggregation Database (gnomAD, <http://gnomad.broadinstitute.org>). For cases with data from parental samples, we evaluated *de novo* vs. inherited status of candidate variants of interest. For splicing variants, we used the splicing prediction score from *Alamut Visual-2.10*, which incorporates the splicing tools MaxEnt, NNSPLICE, and HSF.

Literature cohort

In order to identify additional cases for phenotypic comparison and to evaluate whether a given variant was novel or previously reported and whether there might be data supporting pathogenicity, we performed a literature search (PubMed, accessed June 2018, with search parameters “Sudden Infant Death” [Mesh] AND “Sodium Channels” [Mesh] resulting in the identification of 43 studies. In addition, we searched the Human Gene Mutation Database (<http://www.hgmd.cf.ac.uk/>, accessed June 2018) for each of the VGSCs genes to identify any possible variants not found in the literature search, identifying 13 additional studies with cases of SIDS or SUDC and reported variants in sodium channel-related genes.

Structural protein modeling

We assessed genotype-phenotype correlation by comparing the locations of variants and the phenotypic features associated with each variant using the human Na_v1.7 (*SCN9A*) protein model described by Huang et al [51]. We analyzed the position of the variants of our cohort along with additional variants identified through our literature search (S1 Table). Three of our cases' variants have been previously reported in literature [9,27]. We focused on exonic variants since intronic, splicing, and truncating variants cannot be annotated onto the three-dimensional protein sequence. Illustrations were generated using PyMol.

In silico predictions

Functional prediction scores were obtained from the dbNSFP database version 3.5 (August 2017, <http://varianttools.sourceforge.net/>). In total, we used six pathogenicity prediction scores (SIFT, Polyphen-2-HVAR, Polyphen-2-HDIV, Mutation Assessor, FATHMM, and LRT). We classified a variant as “damaging” when the majority of the tools predicted a functional effect for the variant (i.e., a minimum of 4 out of 6 tools). Splicing variants are considered “possibly damaging” or “damaging” when they have a likelihood of 50% or more to affect splicing. For splicing variants, we used the splicing prediction score from Alamut Visual-2.10, which is calculated from the splicing tools MaxEnt, NNSPLICE, and HSF.

Parazscore

Based on the linear amino acid sequence of *SCN9A* (canonical transcript ENST00000409672, CCDS46441), we compared the position of 74 missense variants in all sodium channel gene paralogs against variants found in the general population using gnomAD. We evaluated the amino acid gene-family paralog conservation score using the Parazscore [52] (<http://mbv.broadinstitute.org>), which leverages amino acid

conservation across gene-family members, assuming that conserved sites are more likely to be important for protein function and thus more likely to be present in patients than in controls. Statistical comparison between the variant counts of patients vs. gnomAD was conducted using a two-tailed t-test with nominal two-sided p-values <0.05 considered significant.

Three-dimensional mapping of amino acid substitutions in VGSC-related genes

In order to assess for a genotype-phenotype correlation across gene-family paralogs, we compared the position of all missense variants from our own cohort and from literature onto a 3-dimensional Na_v1.7 structure model. Since no atomic structure of any mammalian Na_v channel is available, we used the recently published Na_v1.7 structure model [51] that has been established on the cryo-EM structure of a rabbit Cav channel Cav1.1.

Legend

Fig 1: SCN patient variant evolutionary conservation and population constrained assessment. The SCN patient variant paralog conservation score (Parazscore) is shown across the linear protein sequence. Parazscore values range from negative values, representing less conservation at a given amino acid position, to positive values, representing high conservation, with the highest value depicting identical amino acids are present in all related proteins. A) The Parazscore is shown for SCN variants that are predicted to be pathogenic. B) The Parazscore is shown for SCN variants that are predicted to be conflicting. Color scale: purple = SCN1A, turquoise = SCN3A, yellow = SCN4A, orange = SCN4A and SCN10A, blue = SCN5A, green = SCN9A, red = SCN10A.

Supporting information

S1 Fig. Pathogenic *SCN* patient variants are more likely to be localized in the transmembrane regions. The distribution of the paralogues of the *SCN* patient variants is shown on a two-dimensional protein model of the *SCN9A* protein. Variants predicted to be pathogenic are shown in red. Variants predicted to be benign or conflicting are shown in green.

S2 Fig. *SCN* patient variant distribution on a three-dimensional protein model.

The distribution of the paralogues of the *SCN* patient variants is shown on a three-dimensional protein model of the *SCN9A* protein, described by Huang et al[51]. The backbone of the protein is shown in white, and disease-associated variants are shown as red spheres.

S1 Table. All variants in VGSC genes in patients with SIDS or SUDC

Legend: \wedge patient has two variants in *SCN5A*; \ast patient has two variants in *SCN5A*, \blacklozenge carries a variant *in* *SCN5A* and *SCN1B* (both inherited from father), \circ compound heterozygous for *SCN5A*, \square compound heterozygous for *SCN1A*. AF = allele frequency; D = deleterious; gnomAD = Genome Aggregation Database; GOF = gain of function; H = high; n patients = number of patients; L = low; LOF = loss of function; LRT = likelihood ratio test; M = medium; MA = Mutation Assessor; N = neutral; P = pathogenic; PP-2 = PolyPhen2; SIFT = Sorting Intolerant from Tolerant; T = tolerant. Transcripts used: *SCN1A* (NM_001165963.1), *SCN3A* (NM_0006922.3), *SCN4A* (NM_000334.3), *SCN5A* (NM_198056.2), *SCN9A* (NM_002977.3), *SCN10A* (NM_006514.2), *SCN1B* (NM_199037.4), *SCN3B* (NM_018400.3), *SCN4B* (NM_174934.3).

S2 Table. Patients with variants at a paralog position

Legend: AF = allele frequency; GOF = gain of function; LOF = loss of function; N/A = not available. Variants in bold were identified in our cohort. Transcripts used: *SCN1A* (NM_001165963.1), *SCN3A* (NM_0006922.3), *SCN4A* (NM_000334.3), *SCN5A* (NM_198056.2), *SCN9A* (NM_002977.3), *SCN10A* (NM_006514.2), *SCN1B* (NM_199037.4), *SCN3B* (NM_018400.3), *SCN4B* (NM_174934.3).

Acknowledgments

The authors are grateful to all of the families who participated and continue to participate in research on SIDS, SUDC, and SUDEP. We are deeply indebted to Dr. Hannah C. Kinney and her dedication to Robert's Program; her neuropathological analysis of SIDS and SUDC patient samples provided a major contribution to the present study. We thank Kalen Fletcher for facilitating patient enrollment at Robert's Program at Boston Children's Hospital.

Funding

A.M.R. is supported by a Fellowship of the Belgian American Educational Foundation (<http://www.baef.be/documents/home.xml>) and by a Fulbright Program grant sponsored by the Bureau of Educational and Cultural Affairs of the United States Department of State and administered by the Institute of International Education (<https://www.cies.org>). We are also grateful for support from the the Citizens United for Research in Epilepsy Isaac Stone Award (<https://www.cureepilepsy.org>) (A.M.R., R.D.G., A.H.P.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Filiano JJ, Kinney HC. A perspective on neuropathological findings in victims of the sudden infant death syndrome: The triple-risk model. *Biol Neonate*. 1994;65(3–4):194–7.
2. Goldstein RD, Kinney HC, Willinger M. Sudden Unexpected Death in Fetal Life Through Early Childhood. *Pediatrics* [Internet]. 2016;137(6):e20154661–e20154661. Available from: <http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2015-4661>
3. Kinney HC, Cryan JB, Haynes RL, Paterson DS, Haas EA, Mena OJ, et al. Dentate gyrus abnormalities in sudden unexplained death in infants: morphological marker of underlying brain vulnerability. *Acta Neuropathol*. 2015;129(1):65–80.
4. Kinney HC, Poduri AH, Cryan JB, Haynes RL, Teot L, Sleeper LA, et al. Hippocampal formation maldevelopment and sudden unexpected death across the pediatric age spectrum. *J Neuropathol Exp Neurol*. 2016;75(10):981–97.
5. Houser CR. Granule cell dispersion in the dentate gyrus of humans with temporal lobe epilepsy. *Brain Res*. 1990;535(2):195–204.
6. Noebels J. Hippocampal abnormalities and sudden childhood death. *Forensic Sci Med Pathol*. 2016;12(2):198–9.
7. Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. *Lancet Neurol* [Internet]. 2016;15(10):1075–88. Available from: [http://dx.doi.org/10.1016/S1474-4422\(16\)30158-2](http://dx.doi.org/10.1016/S1474-4422(16)30158-2)
8. Massey CA, Sowers LP, Dlouhy BJ, Richerson GB. Mechanisms of sudden unexpected death in epilepsy: The pathway to prevention. *Nat Rev Neurol* [Internet]. 2014;10(5):271–82. Available from:

- <http://dx.doi.org/10.1038/nrneurol.2014.64>
9. Brownstein CA, Goldstein RD, Thompson CH, Haynes RL, Giles E, Sheidley B, et al. SCN1A variants associated with sudden infant death syndrome. *Epilepsia*. 2018;(February):56–62.
 10. Goldman AM, Glasscock E, Yoo J, Chen TT, Klassen TL, Noebels JL. Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained. *Sci Transl Med*. 2009;1(2).
 11. Bagnall RD, Crompton DE, Petrovski S, Lam L, Cutmore C, Garry SI, et al. Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy. *Ann Neurol*. 2016;79(4):522–34.
 12. Baruteau AE, Tester DJ, Kapplinger JD, Ackerman MJ, Behr ER. Sudden infant death syndrome and inherited cardiac conditions. *Nat Rev Cardiol*. 2017;14(12):715–26.
 13. Wang D, Shah KR, Um SY, Eng LS, Zhou B, Lin Y, et al. Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths. *Forensic Sci Int [Internet]*. 2014;237:90–9. Available from: <http://dx.doi.org/10.1016/j.forsciint.2014.01.014>
 14. Kato K, Makiyama T, Wu J, Ding WG, Kimura H, Naiki N, et al. Cardiac channelopathies associated with infantile fatal ventricular arrhythmias: From the cradle to the bench. *J Cardiovasc Electrophysiol*. 2014;25(1):66–73.
 15. Winkel BG, Yuan L, Olesen MS, Sadjadieh G, Wang Y, Risgaard B, et al. The role of the sodium current complex in a nonreferred nationwide cohort of sudden infant death syndrome. *Hear Rhythm [Internet]*. 2015;12(6):1241–9. Available from: <http://dx.doi.org/10.1016/j.hrthm.2015.03.013>
 16. Otagiri T, Kijima K, Osawa M, Ishii K, Makita N, Matoba R, et al. Cardiac ion channel gene mutations in sudden infant death syndrome. *PediatrRes*. 2008;64(1530–0447 (Electronic)):482–7.

17. Priori SG, Napolitano C, Giordano U, Collisani G, Memmi M. Brugada syndrome and sudden cardiac death in children. *Lancet*. 2000;355(9206):808–9.
18. Arnestad M, Crotti L, Rognum TO, Insolia R, Pedrazzini M, Ferrandi C, et al. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. *Circulation*. 2007;115(3):361–7.
19. Plant LD, Bowers PN, Liu Q, Morgan T, Zhang T, State MW, et al. A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. *J Clin Invest*. 2006;116(2):430–5.
20. Millat G, Kugener B, Chevalier P, Chahine M, Huang H, Malicier D, et al. Contribution of long-QT syndrome genetic variants in sudden infant death syndrome. *Pediatr Cardiol*. 2009;30(4):502–9.
21. Glengarry JM, Crawford J, Morrow PL, Stables SR, Love DR, Skinner JR. Long QT molecular autopsy in sudden infant death syndrome. *Arch Dis Child*. 2014;99(7):635–40.
22. Turillazzi E, La Rocca G, Anzalone R, Corrao S, Neri M, Pomara C, et al. Heterozygous nonsense SCN5A mutation W822X explains a simultaneous sudden infant death syndrome. *Virchows Arch*. 2008;453(2):209–16.
23. Tester DJ, Ackerman MJ. Sudden infant death syndrome: How significant are the cardiac channelopathies? *Cardiovasc Res*. 2005;67(3):388–96.
24. Wedekind H, Smits JPP, Schulze-Bahr E, Arnold R, Veldkamp MW, Bajanowski T, et al. De Novo Mutation in the SCN5A Gene Associated With Early Onset of Sudden Infant Death. *Circulation [Internet]*. 2001;104(10):1158–64. Available from: <http://circ.ahajournals.org/cgi/content/abstract/104/10/1158>
25. Ba IG, Jana K, Dsc WAC, Mcdonald T V. Infant sudden death : Mutations responsible for impaired Nav1 . 5 channel trafficking and function.
26. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, et al. An

- international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. *Hear Rhythm* [Internet]. 2010;7(1):33–46. Available from: <http://dx.doi.org/10.1016/j.hrthm.2009.09.069>
27. Halvorsen M, Petrovski S, Shellhaas R, Tang Y, Crandall L, Goldstein D, et al. Mosaic mutations in early-onset genetic diseases. *Genet Med*. 2016;18(7):746–9.
 28. Howell KB, McMahon JM, Carvill GL, Tambunan D, Mackay MT, Rodriguez-Casero V, et al. SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. *Neurology* [Internet]. 2015;85(11):958–66. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26291284>
 29. Veeramah KR, O'Brien JE, Meisler MH, Cheng X, Dib-Hajj SD, Waxman SG, et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. *Am J Hum Genet* [Internet]. 2012;90(3):502–10. Available from: <http://dx.doi.org/10.1016/j.ajhg.2012.01.006>
 30. Johannesen KM, Gardella E, Sche I, Howell K, Smith DM, Helbig I, et al. Early mortality in SCN8A -related epilepsies. 2018;143(April):79–81.
 31. Catterall WA. Voltage-gated sodium channels at 60 : structure , function and pathophysiology. 2012;11:2577–89.
 32. Catterall WA. Structure and function of voltage-gated sodium channels at atomic resolution. 2014;1:35–51.
 33. Brackenbury WJ, Isom LL. Na⁺ channel ?? subunits: Overachievers of the ion channel family. *Front Pharmacol*. 2011;SEP(September):1–11.
 34. Männikkö R, Wong L, Tester DJ, Thor MG, Sud R, Kullmann DM, et al. Dysfunction of Nav1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study. *Lancet* [Internet]. 2018;0(0). Available from:

- [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)30021-7/supplemental](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30021-7/supplemental)
35. Neubauer J, Lecca MR, Russo G, Bartsch C, Medeiros-Domingo A, Berger W, et al. Post-mortem whole-exome analysis in a large sudden infant death syndrome cohort with a focus on cardiovascular and metabolic genetic diseases. *Eur J Hum Genet* [Internet]. 2017;25(4):404–9. Available from: <http://dx.doi.org/10.1038/ejhg.2016.199>
 36. Denti F. Multiple genetic variations in sodium channel subunits in a case of Sudden Infant Death Syndrome.
 37. Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012;491(7422):56–65.
 38. Hu D, Barajas-Martínez H, Medeiros-Domingo A, Crotti L, Veltmann C, Schimpf R, et al. A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Nav1.5 and Kv4.3 channel currents. *Hear Rhythm*. 2012;9(5):760–9.
 39. Tan BH, Pundi KN, Van Norstrand DW, Valdivia CR, Tester DJ, Medeiros-Domingo A, et al. Sudden infant death syndrome-associated mutations in the sodium channel beta subunits. *Hear Rhythm* [Internet]. 2010;7(6):771–8. Available from: <http://dx.doi.org/10.1016/j.hrthm.2010.01.032>
 40. Gal L, Korff CM, Monso-hinard C, Mund MT, Morris M, Malafosse A, et al. BRIEF COMMUNICATION A case of SUDEP in a patient with Dravet syndrome with SCN1A mutation. 2010;51(9):1915–8.
 41. Cooper MS, Mcintosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, et al. Mortality in Dravet syndrome. *Epilepsy Res* [Internet]. 2016;128:43–7. Available from: <http://dx.doi.org/10.1016/j.eplesyres.2016.10.006>
 42. Myers KA, Scheffer IE, Symonds LEBJD, Zuberi SM, Clegg R, Sadleir LG, et al. Heart rate variability in epilepsy : A potential biomarker of sudden

- unexpected death in epilepsy risk. 2018;(May):1–9.
43. Brunklaus A, Ellis R, Reavey E, Semsarian C, Zuberi SM. Genotype phenotype associations across the voltage-gated sodium channel family. *J Med Genet.* 2014;51(10):650–8.
 44. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405–24.
 45. Wallace RH, Hodgson BL, Grinton BE, Gardiner RM, Robinson R, Rodriguez-Casero V, et al. Sodium channel alpha1-subunit mutations in severe myoclonic epilepsy of infancy and infantile spasms. *Neurology [Internet].* 2003;61(6):765–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/14504318>
<http://www.ncbi.nlm.nih.gov/sites/entrez>
 46. Ackerman MJ, Splawski I, Makielski JC, Tester DJ, Will ML, Timothy KW, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: Implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. *Hear Rhythm.* 2004;1(5):600–7.
 47. Auerbach DS, Jones J, Clawson BC, Offord J, Lenk GM, Ogiwara I, et al. Altered Cardiac Electrophysiology and SUDEP in a Model of Dravet Syndrome. *PLoS One.* 2013;8(10):1–15.
 48. Kim Y, Jr DRN, George B, Invest JC, Kim Y, Bravo E, et al. Severe peri-ictal respiratory dysfunction is common in Dravet syndrome. 2018;128(3):1141–53.
 49. Olson HE, Kelly M, LaCoursiere CM, Pinsky R, Tambunan D, Shain C, et al. Genetics and genotype–phenotype correlations in early onset epileptic encephalopathy with burst suppression. *Ann Neurol.* 2017;81(3):419–29.
 50. Gudbjartsson H, Georgsson GF, Gudjónsson SA, Valdimarsson RP,

- Sigurdsson JH, Stefánsson SK, et al. GORpipe: A query tool for working with sequence data based on a Genomic Ordered Relational (GOR) architecture. *Bioinformatics*. 2016;32(20):3081–8.
51. Huang W, Liu M, Yan SF, Yan N. Structure-based assessment of disease-related mutations in human voltage-gated sodium channels. *Protein Cell*. 2017;8(6):401–38.
52. Lal D, May P, Samocha KE, Kosmicki JA, Robinson B, Møller RS, et al. Gene family information facilitates variant interpretation and identification of disease-associated genes equally contributing first authors corresponding author
Address for Correspondence : Mark J . Daly Chief , Analytic and Translational Genetics Unit M. 2017;



